Becton Dickinson Files Quarterly 10-Q as Q3 Earnings Report Looms
The medical technology giant submitted its quarterly disclosure to the SEC ahead of its scheduled third-quarter results announcement.
Regulatory Filing Precedes Earnings
Becton, Dickinson and Company (BDX) filed its quarterly 10-Q report with the Securities and Exchange Commission on August 6, according to SEC EDGAR filings. The regulatory disclosure comes as the medical technology company, with a market capitalization of approximately $47 billion, prepares to release its third-quarter 2026 financial results.
The Franklin Lakes, New Jersey-based manufacturer of medical devices and laboratory equipment last traded at $170.66. The company is scheduled to report Q3 2026 results later today, followed by its quarterly earnings conference call, according to MarginX data.
Upcoming Corporate Actions
Beyond today's earnings report, Becton Dickinson shareholders have a cash dividend of $1.05 per share on the calendar, scheduled for September 9, 2026, MarginX data shows. The dividend represents part of the company's consistent return-of-capital strategy to investors.
Investors will also be monitoring the Federal Open Market Committee's rate decision and economic projections scheduled for September 16, which could influence sentiment across the broader healthcare sector and capital-intensive medical device manufacturers like BDX.
Recent Insider Activity
Recent insider transactions show modest equity-based compensation activity at the executive level. Robert Luther Huffines received an award of 189 shares, while Carrie L. Byington was awarded 94 shares, according to MarginX data. Director Michael Feld executed a sale of 75 shares. These transactions are typical of ongoing compensation and portfolio management activities among corporate leadership.
Company Profile
Becton Dickinson operates as one of the largest global medical technology companies, manufacturing and selling medical devices, instrument systems, and reagents used by healthcare institutions, physicians, life science researchers, and the general public. The company's product portfolio spans medication management, pharmaceutical systems, diabetes care, and diagnostic systems.
The 10-Q filing provides quarterly financial details and management discussion that will be scrutinized alongside today's earnings announcement for insights into operational performance across BDX's diversified healthcare technology platform.
This article was generated by MarginX from public news on 2026-08-06. It is not investment advice.